Inhibitors of human mitotic kinesin Eg5: Characterization of the 4-phenyl-tetrahydroisoquinoline lead series
摘要:
In a high-throughput screening effort, a series of tetrahydroisoquinolines was identified as modest inhibitors of human Eg5. A medicinal chemistry optimization effort led to the identification of R-4-(3-hydroxyphenyl)-N,N-7,8-tetramethyl-3,4-dihydroisoquinoline-2(1 H)-carboxamide (32a) its a potent inhibitor of human Eg5 (ATPase IC50 104 nM) with good anti-proliferative activity in A2780 cells (IC50 234 nM). (C) 2006 Elsevier Ltd. All rights reserved.
Inhibitors of human mitotic kinesin Eg5: Characterization of the 4-phenyl-tetrahydroisoquinoline lead series
摘要:
In a high-throughput screening effort, a series of tetrahydroisoquinolines was identified as modest inhibitors of human Eg5. A medicinal chemistry optimization effort led to the identification of R-4-(3-hydroxyphenyl)-N,N-7,8-tetramethyl-3,4-dihydroisoquinoline-2(1 H)-carboxamide (32a) its a potent inhibitor of human Eg5 (ATPase IC50 104 nM) with good anti-proliferative activity in A2780 cells (IC50 234 nM). (C) 2006 Elsevier Ltd. All rights reserved.
Inhibitors of human mitotic kinesin Eg5: Characterization of the 4-phenyl-tetrahydroisoquinoline lead series
作者:Christine M. Tarby、Robert F. Kaltenbach、Tram Huynh、Andrew Pudzianowski、Henry Shen、Marie Ortega-Nanos、Steven Sheriff、John A. Newitt、Patricia A. McDonnell、Neil Burford、Craig R. Fairchild、Wayne Vaccaro、Zhong Chen、Robert M. Borzilleri、Joseph Naglich、Louis J. Lombardo、Marco Gottardis、George L. Trainor、Deborah L. Roussell
DOI:10.1016/j.bmcl.2006.01.056
日期:2006.4
In a high-throughput screening effort, a series of tetrahydroisoquinolines was identified as modest inhibitors of human Eg5. A medicinal chemistry optimization effort led to the identification of R-4-(3-hydroxyphenyl)-N,N-7,8-tetramethyl-3,4-dihydroisoquinoline-2(1 H)-carboxamide (32a) its a potent inhibitor of human Eg5 (ATPase IC50 104 nM) with good anti-proliferative activity in A2780 cells (IC50 234 nM). (C) 2006 Elsevier Ltd. All rights reserved.